The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
Sign in to access this content
Sign InBrokerages have issued 'Moderate Buy' ratings for both DexCom (DXCM) and Cadence Design Systems (CDNS), reflecting positive growth prospects in the healthcare technology and design software sectors. DexCom received a consensus target price of $85.00 from 25 analysts, supported by strong institutional backing for its medical device portfolio. Meanwhile, Cadence Design Systems is gaining momentum following the launch of its new 'ChipStack AI Super Agent' technology, a sophisticated AI-driven tool for chip design. Despite the optimistic analyst outlook, both companies have experienced notable insider selling activity recently. Cadence insiders, in particular, liquidated approximately $18.5 million in shares over the last 90 days. Investors are currently weighing these technological advancements and analyst confidence against the potential signals from recent insider liquidations.